FEDERALhearing transcript

Congressional Hearing on Prescription Drug Supply Chain and Pricing

Original title: LOWERING PRESCRIPTION DRUG PRICES: DECON-STRUCTING THE DRUG SUPPLY CHAIN

January 1, 2022

prescription drugs healthcare costs supply chain pharmaceutical industry health policy

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing provides a public record of testimony from pharmaceutical manufacturers and pharmacy benefit managers regarding the mechanisms that determine the final cost of medications for patients.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical Manufacturers

These companies are subject to legislative scrutiny regarding their pricing models and supply chain practices.

Pharmacy Benefit Managers (PBMs)

PBMs are involved in the supply chain and are subject to oversight regarding their role in drug cost negotiations.

Patients

Patients are the end-users of prescription drugs and are affected by the pricing outcomes resulting from supply chain dynamics.

What changed

Last recorded activity January 1, 2022.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a May 9, 2019, House Subcommittee on Health hearing. Lawmakers and industry representatives discussed the complexities of the prescription drug and factors influencing drug prices.

Key Facts

The hearing took place on May 9, 2019, before the House Subcommittee on Health.
The session focused on deconstructing the drug supply chain to understand factors affecting prescription drug prices.
Testimony was provided by representatives from pharmaceutical manufacturers (Pfizer, Amgen, Exelixis).
Testimony was provided by representatives from pharmacy benefit managers and pharmacy services (Express Scripts, Navitus Health Solutions, Blue Cross Blue Shield, Ascension).
The document includes prepared statements and answers to follow-up questions from the witnesses.

Why It Matters

The hearing provides a public record of testimony from pharmaceutical manufacturers and pharmacy benefit managers regarding the mechanisms that determine the final cost of medications for patients.

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to examine the prescription drug and identify the factors that contribute to the final cost of drugs for consumers.

Who testified at this hearing?

Witnesses included executives from pharmaceutical companies like Pfizer, Amgen, and Exelixis, as well as representatives from pharmacy benefit managers and health systems like Express Scripts, Navitus, Blue Cross Blue Shield, and Ascension.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Multi-stakeholder approach to drug pricing

The hearing demonstrates a legislative effort to examine the entire supply chain, including both manufacturers and intermediaries, rather than focusing solely on drug manufacturers.

Pfizer Amgen Express Scripts Blue Cross Blue Shield

Connected Entities

organizationSubcommittee on Health“The body within the House Committee on Energy and Commerce that held the hearing”Map →

organizationExpress Scripts“Represented by Amy Bricker, Senior Vice President.”Map →

organizationExelixis“Represented by Jeffrey J. Hessekiel, Executive Vice President.”Map →

organizationPfizer“Represented by Justin McCarthy, Senior Vice President.”Map →

organizationAscension“Represented by Lynn Eschenbacher, Chief Pharmacy Officer.”Map →

personMichael C. Burgess“Ranking Member of the Subcommittee on Health.”Map →

organizationNavitus Health Solutions“Represented by Brent Eberle, Chief Pharmacy Officer.”Map →

organizationAmgen“Represented by Kave Niksefat, Vice President.”Map →

organizationBlue Cross Blue Shield“Represented by Estay Greene, Vice President.”Map →

personAnna G. Eshoo“Chairwoman of the Subcommittee on Health.”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level

Publisher tools